Stable isotope labeling kinetics of neurofilament light in vitro and in vivo
Preprint
Abstract
Importance: Neurofilament light (NfL) is elevated in CSF and blood across a range of traumatic, inflammatory and neurodegenerative diseases of the central nervous system, and has been increasingly included in clinical trials as an outcome measure of target engagement. Interpreting trajectories of NfL post-treatment has been challenging, prompting a greater need and focus on understanding its pathophysiology. Objective: We measured NfL kinetics in the human central nervous system using stable isotope labeling kinetics (SILK). Design: Observational study. Participants underwent SILK protocol. Infusion of 16 hours with 4mg/kg/h and follow-up lumbar punctures scheduled at 7, 14, 60 and 120 days post-labeling. Setting: Referral center – specialist neurology clinic. Participants: Participants with diagnosed primary tauopathies (n=10) were recruited to the Human CNS Tau Kinetics in Tauopathies (TANGLES) study. A control case was examined post-mortem to assess the technical background of the SILK method. Exposure: Intravenous infusion of 13 C 6 -leucine, with rates of label incorporation representative of fractional synthesis and fractional clearance rates in vivo and in vitro . Main outcome and Measure: Level of incorporation of 13 C 6 -leucine tracer into newly-translated NfL divided by the pool of NfL with previously incorporated 12 C 6 -leucine, expressed as a percentage tracer-to-tracee (TTR) ratio. Results: NfL is rapidly translated in human brain within hours but takes 53 – 162 days to appear in cerebrospinal fluid (CSF). Labeled NfL remains detectable in post-mortem brain tissue 1.5 years post-labeling, indicating an extremely slow turnover in the human CNS. Together, these data suggest the greatest contribution of CSF NfL in neurodegeneration is from slow release of a large pool of previously translated NfL. However, release of newly translated NfL makes a significant contribution. Conclusion and relevance: Rapid increases in CSF NfL seen within weeks of disease processes or interventions are likely to reflect release of pre-existing NfL from damaged neurons, but later increases in NfL (>3 months) may also reflect new NfL translation and release. Clinical trials using NfL as an outcome measure to track neurodegeneration would particularly benefit from substantially longer follow-up periods due to the slow turnover of the protein in the central nervous system.Keywords
This publication has 37 references indexed in Scilit:
- Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer DiseaseJAMA Neurology, 2022
- Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in NeurologyJAMA Neurology, 2019
- NFL is a marker of treatment response in children with SMA treated with nusinersenJournal of Neurology, 2019
- Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac ArrestJAMA Neurology, 2019
- Tau Kinetics in Neurons and the Human Central Nervous SystemNeuron, 2018
- Neurofilament subunits are integral components of synapses and modulate neurotransmission and behavior in vivoMolecular Psychiatry, 2015
- Neurochemical Aftermath of Amateur BoxingArchives of Neurology, 2006
- Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivoNature Medicine, 2006
- Neurofibrillary axonal swellings and amyotrophic lateral sclerosisJournal of the Neurological Sciences, 1984
- Presence of neurofilament protein in Alzheimer's neurofibrillary tangles (ANT)Acta Neuropathologica, 1979